<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Frequent blood transfusions are necessary in <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> because of decreased hematopoietic function </plain></SENT>
<SENT sid="1" pm="."><plain>In order to maintain the <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level and to decrease the need for blood transfusion, human ceruloplasmin was used for the treatment of 73 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>A marked beneficial effect was obtained in 16 cases </plain></SENT>
<SENT sid="3" pm="."><plain>The treatment was moderately effective in 17 cases, slightly effective in eight cases, and ineffective in 32 cases </plain></SENT>
<SENT sid="4" pm="."><plain>The usual dose of ceruloplasmin was 15 mg/day, but it was varied according to symptoms </plain></SENT>
<SENT sid="5" pm="."><plain>Side effects were minimal when ceruloplasmin was administered by slow intravenous injection </plain></SENT>
</text></document>